Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2016-06-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于对全资公司北京华方科泰医药有限公司减资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the reduction of registered capital of a wholly-owned subsidiary by the company. It details the background, purpose, and impact of the capital reduction. There is no financial report, audit, or earnings data presented. The document is a formal announcement about a capital structure change (reduction of registered capital) within the company and its subsidiary. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is CAP with high confidence.
2016-06-28 Chinese
关于全资公司医药商业有限公司与招商银行昆明分行滇池路支行合作在电商平台中搭建互联网融资平台暨对外担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding a cooperation agreement between its wholly-owned subsidiary and a bank to establish an internet financing platform and provide external guarantees. It details the guarantee amount, the nature of the guarantee, board opinions, independent director opinions, and cumulative guarantee amounts. The document is relatively short (1521 characters) and focuses on a specific financing and guarantee arrangement rather than presenting comprehensive financial data or results. It is not an annual or interim report, audit report, earnings release, or any form of detailed financial statement. It is also not a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees.
2016-06-28 Chinese
信息披露管理制度（2016年修订）
Governance Information Classification · 95% confidence The document is titled as an "Information Disclosure Management System" for Kunming Pharmaceutical Group Co., Ltd., revised in 2016. It extensively details the company's internal policies, principles, responsibilities, procedures, and legal obligations regarding information disclosure. It references relevant laws, regulatory bodies (China Securities Regulatory Commission, Shanghai Stock Exchange), and rules governing disclosure. The content is a governance and compliance manual rather than a financial report, earnings release, or announcement. It does not contain financial statements, audit results, voting results, or any event-specific disclosures. It is a detailed governance document about how the company manages information disclosure, including roles of directors, board secretary, and procedures for reporting. Therefore, the document fits best under Governance Information (CGR). The document length (8494 characters) and detailed procedural content support this classification with high confidence.
2016-06-28 Chinese
关于控股公司昆明贝克诺顿制药有限公司对其全资公司昆明贝克诺顿药品销售公司增资的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding a capital increase (增资) by its holding company Kunming Becknorton Pharmaceutical Co., Ltd. to its wholly-owned subsidiary Kunming Becknorton Pharmaceutical Sales Co., Ltd. The text details the capital increase amount, the financial status of the subsidiary, the board approval date, and the impact on the parent company. It is a formal announcement about a financing/capital structure change within the corporate group. The document length is short (1325 characters), and it is not a full financial report or audit report but an announcement of a capital increase. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2016-06-28 Chinese
2016年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2016 third extraordinary general meeting of shareholders of Kunming Pharmaceutical Group Co., Ltd. It includes information about the meeting date, location, attendance, voting results on various proposals including amendments to the company charter and a restricted stock incentive plan, and legal witness statements. The content focuses on the official voting results and decisions made by shareholders at the meeting. It is not a report or presentation but an official announcement of voting outcomes from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail confirm it is not a brief notice or a report publication announcement but a full voting results announcement.
2016-06-28 Chinese
2016年第三次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the procedures and legality of a specific shareholders' meeting (the 2016 third extraordinary shareholders' meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the meeting, concluding that the meeting and resolutions were lawful and valid. This is not a report of the meeting itself, nor is it an announcement of voting results. Instead, it is a legal opinion related to the shareholders' meeting. Such legal opinions related to shareholder meetings typically fall under Regulatory Filings (RNS) as they do not fit into other specific categories like Declaration of Voting Results (DVA) or Proxy Solicitation (PSI). The document length is short (1474 characters), and it is not a report publication announcement. Therefore, the best classification is Regulatory Filings (RNS).
2016-06-28 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.